一期与两期乳房再造术后乳房假体取出风险比较
这项多中心回顾性研究纳入2010至2016年接受乳房切除后即刻一期或两期假体乳房再造的383例女性,比较假体取出率、总体并发症率和二次修整率。一期组假体取出率19.9%高于两期组11.3%(p=0.082),总体并发症率35.7%对19.9%(p=0.008),二次修整率29.8%对20.3%(p=0.156)。多因素分析中两方案取出与并发症风险无显著差异,但预防性切除者一期再造后取出风险更高(OR=4.49)。
要点
- 一期与两期假体乳房再造的假体取出率和并发症率在多因素分析中无显著差异。
- 一期再造的二次修整率数值上高于两期再造(29.8%对20.3%),但差异未达统计学显著(p=0.156)。
- 预防性乳房切除女性一期再造后假体取出风险显著高于两期(OR=4.49,95%CI 1.10-18.3)。
核心结论
- 作者认为一期与两期即刻假体乳房再造的假体取出率和并发症率相当,一期再造的二次修整更多,预防性乳房切除者一期再造后假体取出风险显著更高。
研究设计与样本
- 多中心回顾性研究,纳入2010至2016年接受乳房切除后即刻一期或两期假体乳房再造的全部患者,共383例女性。
- 主要结局为乳房再造后60天内组织扩张器和/或假体取出,次要结局为总体并发症率和二次修整。
主要发现
- 一期组假体取出率19.9%高于两期组11.3%(p=0.082)。
- 一期组总体并发症率35.7%高于两期组19.9%(p=0.008)。
- 一期组二次修整率29.8%高于两期组20.3%(p=0.156)。
- 校正吸烟史、保留乳头乳房切除、新辅助放疗和切除乳腺组织重量后,一期与两期再造的取出风险(OR=1.55,95%CI 0.67-3.58,p=0.301)和并发症风险(OR=1.85,95%CI 0.92-3.37,p=0.084)无显著差异。
- 预防性手术女性一期再造后取出风险高于两期再造(OR=4.49,95%CI 1.10-18.3,p=0.037);治疗性乳房切除女性中再造类型与取出风险无关联(OR=0.82,95%CI 0.24-2.79,p=0.74)。
临床怎么用
- 作者指出,需决定是否行预防性乳房切除的女性应知晓一期假体乳房再造后假体取出风险显著更高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To date, both one- and two-stage techniques are used in immediate 'implant-based breast reconstruction' (IBBR) after mastectomy. Because it is still unknown what technique offers the best clinical outcomes, a multicenter retrospective study was conducted to compare both breast reconstruction techniques. METHODS: All patients, who underwent a mastectomy followed by immediate one- or two-stage IBBR during 2010 - 2016 were included. Our primary outcome measure was explantation of the 'tissue expander' (TE) and/ or implants within 60 days after breast reconstruction. Secondary outcomes were overall complication rate and secondary corrections. FINDINGS: Among a total of 383 women, TE/ implant explantation rate was higher in one-stage (19.9%) than in two-stage (11.3%) treated patients (p = 0.082). Overall complication rate (35.7% and 19.9% respectively, p = 0.008) and secondary corrections (29.8% and 20.3% respectively, p = 0.156) were also higher in one-stage compared to two-stage IBBR respectively. However, explantation (OR = 1.55; 95%CI = 0.67-3.58, p = 0.301) and complication (OR = 1.85; 95%CI = 0.92-3.37, p = 0.084) rates were comparable in one- and two-stage IBBR in our stratified multivariate logistic regression analyses, when controlling for history of smoking, nipple-sparing mastectomy, neoadjuvant radiation therapy, and removed breast tissue weight. A remarkable outcome in this study is that women treated with prophylactic surgery were more likely to have an explantation of the TE/ implant after a one-stage IBBR (OR = 4.49; 95%CI = 1.10-18.3, p = 0.037) than two-stage IBBR. In contrast, no association between type of IBBR and risk of TE/implants removal was found among women with a therapeutic mastectomy (OR = 0.82; 95%CI = 0.24-2.79, p = = 0.74). CONCLUSION: One- and two-stage IBBR showed a comparable explantation and complication rate in our retrospective study. In one-stage IBBR more secondary corrections were detected. In addition, women who have to decide on a prophylactic mastectomy should be aware of a significantly higher risk of explantation of their implant after one-stage IBBR.
引用
- Theunissen CIJM, Brohet RM, Hu Y, et al. Risk of breast implant removal after one- versus two-stage breast reconstructive surgery. J Plast Reconstr Aesthet Surg. 2021. PMID: 34975002. doi:10.1016/j.bjps.2021.11.112
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。